Skip to main content

Advertisement

SpringerLink
Log in

Small Cell Lung Cancer: Past, Present, and Future

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. It is characterized by its rapid doubling time, high rate of dissemination, and increased sensitivity to chemotherapy and radiation. Although the incidence of SCLC has been steadily decreasing over time, it remains a serious public health problem given its aggressive clinical behavior and the lack of effective therapies. This review looks at the evolution of SCLC treatment and the standard treatments that are currently available, including platinum-based combination chemotherapy, hyperfractionated thoracic radiation, and prophylactic cranial irradiation. The development of novel therapies for SCLC has been lagging behind, but completed clinical trials and ongoing investigations are helping us define what will be the best therapeutic targets for this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society: What is Small Cell Lung Cancer? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_3x_How_Is_Small_Cell_Lung_Cancer_Staged.asp?rnav=cri. Accessed April 13, 2010.

  2. Shepherd FA, Crowley J, Van Houtte P, et al.: The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2:1067–1077.

    Article  PubMed  Google Scholar 

  3. Govindan R, Page N, Morgensztern D, et al.: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539–4544.

    Article  PubMed  Google Scholar 

  4. Chute JP, Chen T, Feigal E, et al.: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999, 17:1794–1801.

    CAS  PubMed  Google Scholar 

  5. Le Chevalier T, Arriagada R: Report on the IASLC Le Havre Workshop on combined modality treatment in small cell lung cancer. Chest 1989, 96:73S–74S.

    PubMed  Google Scholar 

  6. Bremnes RM, Sundstrom S, Aasebo U, et al.: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003, 39:303–313.

    Article  PubMed  Google Scholar 

  7. Gandhi L, Johnson BE: Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006, 4:631–638.

    PubMed  Google Scholar 

  8. Pignon JP, Arriagada R, Ihde DC, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992, 327:1618–1624.

    CAS  PubMed  Google Scholar 

  9. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992,10:890–895.

    CAS  PubMed  Google Scholar 

  10. Choi NC, Herndon JE 2nd, Rosenman J, et al.: Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998, 16:3528–3536.

    CAS  PubMed  Google Scholar 

  11. Turrisi AT 3rd, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265–271.

    Article  CAS  PubMed  Google Scholar 

  12. Lad T, Piantadosi S, Thomas P, et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994, 106:320S–323S.

    Article  CAS  PubMed  Google Scholar 

  13. Green RA, Humphrey E, Close H, Patno ME: Alkylating agents in bronchogenic carcinoma. Am J Med 1969, 46:516–525.

    Article  CAS  PubMed  Google Scholar 

  14. Evans WK, Shepherd FA, Feld R, et al.: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985, 3:1471–1477.

    CAS  PubMed  Google Scholar 

  15. Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83:855–861.

    Article  CAS  PubMed  Google Scholar 

  16. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000, 83:8–15.

    Article  CAS  PubMed  Google Scholar 

  17. Mascaux C, Paesmans M, Berghmans T, et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30:23–36.

    Article  CAS  PubMed  Google Scholar 

  18. Skarlos DV, Samantas E, Kosmidis P, et al.: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994, 5:601–607.

    CAS  PubMed  Google Scholar 

  19. Noda K, Nishiwaki Y, Kawahara M, et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85–91.

    Article  CAS  PubMed  Google Scholar 

  20. Hanna N, Bunn PA Jr, Langer C, et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038–2043.

    Article  CAS  PubMed  Google Scholar 

  21. Lara PN Jr, Natale R, Crowley J, et al.: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530–2535.

    Article  CAS  PubMed  Google Scholar 

  22. Niell HB, Herndon JE 2nd, Miller AA, et al.: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005, 23:3752–3759.

    Article  CAS  PubMed  Google Scholar 

  23. Sculier JP, Berghmans T, Castaigne C, et al.: Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998, 19:141–151.

    Article  CAS  PubMed  Google Scholar 

  24. Hanna NH, Sandier AB, Loehrer PJS, et al.: Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002, 13:95–102.

    Article  CAS  PubMed  Google Scholar 

  25. Schiller JH, Adak S, Cella D, et al.: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19:2114–2122.

    CAS  PubMed  Google Scholar 

  26. O’Brien ME, Ciuleanu TE, Tsekov H, et al.: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441–5447.

    Article  PubMed  Google Scholar 

  27. Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090–2096.

    CAS  PubMed  Google Scholar 

  28. Shepherd FA, Evans WK, MacCormick R, et al.: Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987, 71:941–944.

    CAS  PubMed  Google Scholar 

  29. Sculier JP, Klastersky J, Libert P, et al.: Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. Eur J Cancer 1990, 26:919–921.

    CAS  PubMed  Google Scholar 

  30. von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658–667.

    Google Scholar 

  31. • Socinski MA, Smit EF, Lorigan P, et al.: Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27:4787–4792. The combination of pemetrexed plus carboplatin is inferior to etoposide-carboplatin for the treatment of ED-SCLC.

    Article  CAS  PubMed  Google Scholar 

  32. Eckardt JR, Bentsion DL, Lipatov ON, et al.: Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009, 27:2046–2051.

    Article  CAS  PubMed  Google Scholar 

  33. Onoda S, Masuda N, Seto T, et al.: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006, 24:5448–5453.

    Article  CAS  PubMed  Google Scholar 

  34. Inoue A, Sugawara S, Yamazaki K, et al.: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008, 26:5401–5406.

    Article  CAS  PubMed  Google Scholar 

  35. Jotte R, Conkling P, Reynolds C: Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy [abstract 8028]. J Clin Oncol 2009, 27(Suppl):15s.

    Google Scholar 

  36. Ohe Y, Negoro S, Matsui K, et al.: Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005,16:430–436.

    Article  CAS  PubMed  Google Scholar 

  37. Horn L, Dahlberg SE, Sandler AB, et al.: Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009, 27:6006–6011.

    Article  CAS  PubMed  Google Scholar 

  38. Ready N, Dubek AZ, Wang XF: CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007, 25(Suppl 18S):7563.

    Google Scholar 

  39. • Spigel D, Townley P, Waterhouse D, et al.: Salute: a placebo-controlled, double-blind multicenter, randomized, phase II study of bevacizumab in previously untreated extensive-stage small cell lung cancer. Presented at the 13th World Conference on Lung Cancer. San Francisco, CA; July 31–August 4, 2009. This is a negative randomized phase 2 study comparing bevacizumab in addition to cisplatin/etoposide versus cisplatin/etoposide, showing similar efficacy and increased risk of toxicity.

  40. Spigel DR, Hainsworth JD, Farley, et al.: Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol 2008, 26(Suppl):abstract 7554.

    Google Scholar 

  41. Ramalingam SS, Mack PC, Vokes EE, et al.: Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097). J Clin Oncol 2008, 26(Suppl):abstract 8078.

    Google Scholar 

  42. Arnold AM, Seymour L, Smylie M, et al.: Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007, 25:4278–4284.

    Article  CAS  PubMed  Google Scholar 

  43. Dy GK, Miller AA, Mandrekar SJ, et al.: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16:1811–1816.

    Article  CAS  PubMed  Google Scholar 

  44. Krug LM, Crapanzano JP, Azzoli CG, et al.: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005, 103:2128–2131.

    Article  CAS  PubMed  Google Scholar 

  45. Moore AM, Einhorn LH, Estes D, et al.: Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006, 52:93–97.

    Article  CAS  PubMed  Google Scholar 

  46. Pandya KJ, Dahlberg S, Hidalgo M, et al.: A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007, 2:1036–1041.

    Article  PubMed  Google Scholar 

  47. Owonikoko TK, Stoller RG, Petro D, et al.: Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC). J Clin Oncol 2008, Suppl:abstract 19017.

  48. Suyama H, Igishi T, Ueda Y, et al.: Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells. Oncol Rep 2010, 23:217–222.

    CAS  PubMed  Google Scholar 

  49. Zeitlin BD, Zeitlin IJ, Nor JE: Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008, 26:4180–4188.

    Article  CAS  PubMed  Google Scholar 

  50. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994, 54:6–8.

    CAS  PubMed  Google Scholar 

  51. Rudin CM, Salgia R, Wang X, et al.: Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008, 26:870–876.

    Article  CAS  PubMed  Google Scholar 

  52. Chiappori A, Sereno M, Gabrilovich D, et al.: Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007, 25(Suppl 18):3012.

    Google Scholar 

  53. Auperin A, Arriagada R, Pignon JP, et al.: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999, 341:476–484.

    Article  CAS  PubMed  Google Scholar 

  54. van Oosterhout AG, Boon PJ, Houx PJ, et al.: Follow-up of cognitive functioning in patients with small cell lung cancer. Int J Radiat Oncol Biol Phys 1995, 31:911–914.

    PubMed  Google Scholar 

  55. •• Slotman B, Faivre-Finn C, Kramer G, et al.: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357:664–672. PCI improves PFS and OS in patients with chemosensitive ED-SCLC.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Dr. Lilenbaum has been a consultant or had an advisory role for the following: Genentech; AstraZeneca; YM Biosciences; and Abraxis. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Mount Sinai Cancer Center, Miami Beach, FL, 33140, USA

    Estelamari Rodriguez & Rogerio C. Lilenbaum

Authors
  1. Estelamari Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rogerio C. Lilenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Estelamari Rodriguez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodriguez, E., Lilenbaum, R.C. Small Cell Lung Cancer: Past, Present, and Future. Curr Oncol Rep 12, 327–334 (2010). https://doi.org/10.1007/s11912-010-0120-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-010-0120-5

Keywords

Search

Navigation